Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin for unresectable hepatocellular carcinoma with Child-Pugh B/C liver function
ChiCTR2400094250Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Icaritin in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and Overall survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400094250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094250.